The neuroimaging studies described in this paper were part of a multicenter, randomized, controlled, phase 2b/3 study to evaluate the efficacy and safety of PE with albumin replacement with or without alternated intravenous immunoglobulin (IVIG) in AD patients (AMBAR Trial: EudraCT#: 2011–001,598-25; ClinicalTrials.gov ID: NCT01561053). This evidence concerns the gene ALB and Alzheimer disease.